Fig. 3.

PET/CT scans of 1/5 responding Hodgkin’s lymphoma patients treated with the TNC-A1-targeting radioligand [¹³¹I]I-F16SIP (Tenarad). a Maximum intensity projection image of the baseline FDG PET/CT scan (left), the [¹³¹I]I-F16SIP SPECT/CT scan 24 h post-injection (middle), and the FDG PET/CT scan 4 weeks after [¹³¹I]I-F16SIP treatment (right). b Whole-body images at different time points after 3.33 GBq [¹³¹I]I-F16SIP administration, demonstrating uptake in tumor lesions. A: anterior view, P: posterior view. The figure was originally published in EJNNMI by Aloj et al. [65]. Radioimmunotherapy with Tenarad, a 131I-labeled antibody fragment targeting the extradomain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma (2014) Vol 41(5):867–877